cyrilzakka/clinical-trials huggingface dataset:
Perception of Affordances and Obstacle Crossing in People With Parkinson's Disease and Healthy Adults

This study aims to explore how young adults, older adults and people with Parkinson's disease (PwP), perceive their abilty to cross obstacles while walking, and how this perception is related to their actual performance of obstacle crossing and disease-related motor and cognitive impairments. The study will explore this percepeption and the actual performance in different walking environments(floor, synthetic grass turf). Understanding how people perceive obstacles may help improve rehabilitation methods and reduce the risk of falls. The study will take place at the Motor Performance Laboratory, University of Haifa, and will include walking tasks, eye-tracking measurements, and motor and cognitive assessments.

This study investigates the role of affordance perception - the ability to perceive opportunities for action - during obstacle crossing in people with Parkinson's disease (PwP). Falls are highly prevalent in PwP, often resulting from tripping over obstacles. While previous research has mainly focused on gait impairments, this study uniquely examines the perceptual stage that precedes movement and the association between perception, cognition, and motor performance.

Participants will include 60 PwP and 120 healthy adults (60 older adults and 60 young adults). All participants will perform walking tasks involving obstacle crossing under different environmental conditions (e.g., different obstacle heights and surfaces). Prior to walking, participants will judge whether they can safely cross the obstacle. Eye-tracking glasses will measure visual exploration patterns to assess how participants scan the environment. Additionally, walking variables such as speed and step length, will be recorded using wearable sensors.

The study will explore:

1. Differences in affordance perception between PwP and healthy adults.
2. Associations between motor and cognitive impairments and affordance perception in PwP.
3. How affordance perception relates to gait performance during obstacle crossing.

Results from this study may help to develop new intervention strategies aimed at improving safe walking and obstacle negotiation in PwP.

Eligibility Criteria:
Inclusion Criteria:

* Participants aged 20 to 80 years.
* Ability to walk independently outdoors without assistive devices.
* For Parkinson's Disease (PD) group: Diagnosis of PD confirmed by medical records.
* For healthy control groups: No neurological or orthopedic conditions affecting gait.

Exclusion Criteria:

* Feezing of gait (for PD group only), based on a score greater than 0 on the Freezing of Gait Questionnaire.
* Severe visual impairment that cannot be corrected with glasses or lenses.
* Cognitive impairment, defined as a score below 18 on the telephone-based Mini-Mental State Examination (MMSE).
* Any orthopedic condition, pain, or other medical condition that may affect walking, based on self-report.
Personalized Nutrition Advice for Optimizing Dietary Calcium Intake in MS Patients

The main objective of this study is to measure effectiveness at 6 months of personalized dietary advice versus dietary counseling via delivery of a standard advice sheet for optimizing dietary calcium intake (assessed by a food survey based on CIQUAL\* data) in MS patients with ambulatory monitoring.

\*CIQUAL Data: Table of nutritional food composition available on the ANSES (National Agency for Sanitary Security of Food, Environment and Labour) website, published by the Observatory of the Nutritional Quality of Foods. This table includes 1,500 sheets of 58 nutritional components. The data is integrated into the software for calculating ingesta (DATAMEAL) at the Nîmes University Hospital.

The secondary objectives of this study is to compare the two groups in order to:

A- correlate the impact of the recommendations by sheet or consult with disability, cognitive status, fatigue, depression, quality of life of patients with MS.

B- assess the prevalence of diet changes as an alternative therapy for lactose intolerance in the population and to correlate these changes with dietary calcium intake at baseline (assessed by a food survey based on CIQUAL\* data).

C- assess calcium intake of the patients included via the self-administered frequency questionnaire QALCIMUM® on day 0 and 6 months and to compare them with data obtained by the food survey based on data from CIQUAL.

D- correlate calcium intake of the patients with vitamin D levels at inclusion and establish a biological collection of blood samples from the population.

Eligibility Criteria:
Inclusion Criteria:

* The patient must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* Patient with a confirmed diagnosis of remitting multiple sclerosis
* Ambulatory patient (EDSS score \< 6.5) who has never had a dietary consultation concerning the optimization of calcium intake

Exclusion Criteria:

* The patient is participating in another non-observational study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, under tutorship or curatorship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* The subject is not able to complete a self-administered questionnaire
* Vitamin D deficiency linked to currently active digestive or general diseases
* Moderate or severe renal impairment (creatinine clearance \<60ml / min)
* Situations accompanied by increased vulnerability to hypercalcemia, eg arrhythmia or known heart disease, treatment with digitalis, subjects with nephrolithiasis
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.

Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.


Eligibility Criteria:
Inclusion Criteria:

* Anthracycline and taxane-refractory or intolerant metastatic breast cancer
* Female

Exclusion Criteria:

* Prior treatment with 3 or greater regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines/taxanes.
Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department

Our goal is to study whether giving people low dose ketamine along with morphine when they come to the Emergency Department will help their pain more than giving morphine by itself. There have been many studies showing that low dose ketamine is safe and effective for pain control. Ketamine is frequently used for pain control in ambulances and helicopters transporting injured patients to the hospital and has also been used for pain control in people who have just had surgery. The investigators would like to see if low dose ketamine would be safe and effective for patients with pain in the Emergency Department.

Patients are eligible for the study if they come to the Emergency Department and their treating physician decides to treat them with morphine (with certain exceptions such as pregnant patients and patients with eye injuries). They will be given information about participating in the study and if they agree, they will be given the study drug. The study drug will be either ketamine or salt water (saline). If patients continue to be in pain they will continue to receive doses of morphine just as they would if they were not in the study. If the treating physician feels that morphine alone is not enough, they will be free to choose another pain medication as they would normally.


Eligibility Criteria:
Inclusion Criteria:

* Presenting to Emergency Department in acute pain
* age 18 and over
* determined to require morphine for pain control by treating physician

Exclusion Criteria:

* Patients presenting with headache or head injury
* Patient with eye injury or eye pain
* Nontraumatic chest Pain
* Pregnant patients or women of childbearing potential
* Patients allergic to morphine or ketamine
* Patients with known history of narcotic/alcohol abuse or presenting for narcotic medication refill
* Patients with hypertension: diastolic blood pressure \> 100 OR systolic blood pressure \> 180
* Patient whose pain is so severe that they are unable to give informed consent
* Patients who have had bad experiences to prior hallucinations from any origin
Study to Assess VB-201 in Patients With Psoriasis

The purpose of this study is to examine the efficacy, safety and tolerability of VB-201 as compared with placebo on measures of disease activity in patients with psoriasis.


Eligibility Criteria:
Inclusion Criteria:

* Male or female Patients, ≥18 to ≤75 years of age, who have a diagnosis of chronic plaque psoriasis for at least 6 months
* Non-anorexic subjects with a BMI ≥20
* Psoriasis Area and Severity Index (PASI) score of ≥12
* Plaque psoriasis covering ≥10% of body surface area (BSA)
* Psoriasis severity at least moderate, scoring at least 3 on the 0 to 5 point Physician Global Assessment (PGA) scale

Exclusion Criteria:

* The subject presents with the predominant type of psoriasis as guttate, erythrodermic, inverse, pustular or palmo-plantar or an unstable form of psoriasis
* The subject has not undergone wash-out periods of sufficient duration for the following treatments at Baseline: Topical psoriasis treatments; Systemic, oral or injected, psoriasis treatments; Phototherapy
* The subject anticipates getting enough ultra-violet light during the study to cause psoriasis to improve
* The subject has a known allergy or sensitivity to the study treatment(s) or to any of the excipients contained in the study drug formulation
* History of cancer, the exception is skin cancer
* Has a clinically significant systemic infection within 30 days of Day 0, or a history or presence of recurrent or chronic infection
* Evidence of tuberculosis as indicated by a positive tuberculin skin test or a quantiferon test in subjects known to have a + PPD and a negative chest x-ray at screening
* History of clinically significant hypoglycemia
* Subjects with currently active peptic ulcer / gastroesophageal reflux disease
Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy

Patients with Parkinson's Disease or Multiple System Atrophy (MSA), and symptoms of orthostatic hypotension, are eligible for the study. Each patient will have three weeks of conservative therapy, three weeks of therapy with fludrocortisone, and three weeks of therapy with domperidone. Autonomic testing, a symptom questionnaire, bedside blood pressure testing, and Unified Parkinson Disease Rating Scale (UPDRS) will be performed after each intervention.

Enrolled patients, ages 40-95, must have Parkinson's or MSA, diagnosed by a neurologist, and symptoms of orthostatic hypotension. Each patient will fill out two validated questionnaires to determine if they are candidates for the study. Baseline patient details, such as their medications and UPDRS, will be recorded. Medications must be held stable during the period of the study.

Each patient will then have three weeks of conservative therapy, three weeks of therapy with fludrocortisone, and three weeks of therapy with domperidone. Autonomic testing, a symptom questionnaire, bedside blood pressure testing, and UPDRS will be performed after each intervention.

Eligibility Criteria:
Inclusion Criteria:

* Patients residing in Queensland Australia
* Age 40-95
* Parkinson's Disease or MSA diagnosed by a neurologist
* Symptoms of orthostatic hypotension, as defined by 2 validated questionnaires

Exclusion Criteria:

* Patients with acute cardiomyopathy or cardiac condition
* Patients unable to give consent
* Patients not stable on their Parkinsonian medications
* Patients with another cause for autonomic neuropathy
"Mandometer®" Study for Managing Childhood Obesity

We run a successful clinic in Bristol for children with severe obesity who already demonstrate many features to suggest they are at increased risk of early diabetes and heart disease. However, we have found that young children respond better to simple interventions than do adolescents. We have used a new treatment regimen "Mandometer®" to help our most difficult adolescent cases lose weight. We would like to do a study to see if all adolescents might improve weight loss using this technology compared to what we routinely offer

Childhood obesity is rapidly reaching epidemic proportions in the United Kingdom. Recent studies have indicated a prevalence level for obesity of 15% at 15 years of age. The implications for metabolic, cardiovascular and cancer risk in later life are enormous. The International Obesity Task Force (IOTF) and the European Association for the Study of Obesity (EASO) have identified childhood obesity as a matter for urgent attention. However, there are very few obesity clinics for children in the UK and effective treatment regimens are simply not available. We have developed an obesity clinic at the Royal Hospital for Children in Bristol and observed effective weight reduction in pre-pubertal children. Our simple treatment framework has proved far less effective in adolescence. We have therefore collaborated with an eating disorder clinic from the Karolinska Institute in Sweden to develop a novel therapy to treat obesity using modified equipment originally designed to treat adolescents with DSM-IV eating disorders. Pilot data indicate that adolescents are better able to address the issue of weight reduction within this treatment modality. Having established the software and treatment process we now wish to perform a randomised, control trial to test the efficacy of this new treatment against that currently provided.

Eligibility Criteria:
Inclusion Criteria:

* Obese children and adolescents aged 10-18

Exclusion Criteria:

Children:

* Having associated learning difficulties
* Who have received medication for associated insulin resistance
* Refusal of parent/legal guardian to give informed consent.
The Study of Breast MRI Screening and Proton Magnetic Resonance Spectroscopy

To delineate if the chemical composition (lipid and water) in the presumably normal breast of the high risk women is different from those of the low risk group.

The researchers would like to investigate and compare the chemical composition in the normal breast between high risk women and general population.

Eligibility Criteria:
Inclusion Criteria:

* Women without breast symptoms (without family history of breast cancer; or with at least first-degree relative of breast cancer) with negative mammography and ultrasound result in recent 3 months or contralateral normal breasts from women with newly diagnosed unilateral breast cancer
* 25-75 years old.

Exclusion Criteria:

* renal function impairment
* past history of anaphylactoid reaction to MRI contrast media (Gd-DTPA)
* pregnant or lactating women
* medication of HRT or oral pills in recent 6 months
* past history of surgery of the breast (either side)
* past history of breast cancer
* with breast implant or silicone injection
* past history of cardiac surgery, mechanical valve replacement, aneurismal clip, endotracheal tube or tracheostomy tube, any metallic implants.
Promotion of Active Lifestyle in Thromboembolism Patients

Patients who have suffered a pulmonary thromboembolism used to reduce their activity levels because of the symptoms and the fear to suffer other pulmonary thromboembolism. These patients often have sequelae after the hospitalization that previous studies have associated with a lack of physical activity.

The main objective of this research is to investigate the efficacy of a rehabilitation program for promotion higher activity levels in quality of life and self-perceived discapacity of thromboembolism patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients of both sexes.
* Agreed to participate.
* Thromboembolism patients meeting the diagnosis criteria for this disease.

Exclusion Criteria:

* Neurological or orthopaedic pathologies that limited voluntary movement.
* Cognitive impairment that prevented them from understanding and answering the questionnaires.
* Patients suffering from a previous pulmonary thromboembolism.
* Patients who don´t understand Spanish language
Manual Therapy Versus Conventional Rehabilitation Protocol on Subacromial Pain Syndrome

This study compares the periodic effects of Accelerated rehabilitation protocol (ARP) and Mulligan mobilization with mowement method (MWM) in subacromial pain syndrome patients rehabilitation. Half of the participants will receive ARP, while the other half will receive MWM.


Eligibility Criteria:
Inclusion Criteria:

* to be in the 18-60 age range, to be cooperative during evaluation and treatment and to accept to participate in the study

Exclusion Criteria:

* the presence of adhesive capsulitis, surgical indication or shoulder surgery, cervicothoracic problems (such as stenosis and disc herniation) diagnosed as neurological or inflammatory joint diseases
Familial and Functional Study of Genetic Variants Identified in People With Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder or Resistant Depression

Genetic analyses conducted on patient with psychiatric disorders assessed at the expert centres resulted in the identific action of genetic variants associated with psychiatric disorders (Courtois, 2020). These data require further genetic and functional analyses. The first objective of this study is to investigate the disease-related inheritance of genetic variants in the families of individuals in whom these variants have been identified. The second objective is to explore the functional consequences of disease-associated genetic variants in patients cells and those of their relatives with and without these variants.

The present project aims to enrich existing biocollections with DNA from blood or saliva from relatives of patients identified with genetic variants. In addition, we wish to collect hair follicules from patients with identified genetic variants of interest and their family members who wish to participate in the study. These hair samples with SNA will be used to dedifferentiate the isolated cells into induced pluripotent stem cells (IPSCs), and then to differentiate them into cells expressing the gene of interest, such as neurons or astrocytes, or into more complex systems, such as brain organoids.


Eligibility Criteria:
Inclusion Criteria:

* For patients:
* Subjects suffering from (according to DSM IV criteria) : Bipolar disorder, Unipolar depression, Schizophrenia, Autism spectrum disorder
* Age over 18 years
* Subject affiliated to the social security system
* Including patients under guardianship, curatorship,
* Patients included in the Fondation FondaMental cohort whose genetic analyses have revealed the need for comparative and functional genetic studies.
* Having signed the consent form

For relatives :

* Age over 18 years
* Relative of patient included in the Fondattion FondaMental cohort
* Including relative under guardianship, curatorship
* Having signed the consent
* Affiliated to social security

Exclusion Criteria:

* For all subjects:
* Any condition that, in the opinion of the investigator, would make the subject's participation in the study undesirable or that would compromise compliance with the protocol
* Persons deprived of liberty
* Inability to understand French
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone

The purpose of this study was to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with dexamethasone in participants with Relapsed Refractory Multiple Myeloma (RRMM).


Eligibility Criteria:
Inclusion Criteria:

* Participants having Eastern Co-operative Oncology Group (ECOG) Performance Status less than or equals to (\<=) 1
* Adequate hematological, hepatic and renal function as defined in the protocol
* Participant must have measurable disease of Multiple Myeloma (MM) and received greater than (\>) 3 prior lines of therapy for MM including a Proteasome Inhibitors (PI), an Immunomodulatory Imide Drug (IMiD) and an anti-CD38 mAb or who are refractory to at least PI agent (carfilzomib or bortezomib) and IMiD according to the International Myeloma Working Group (IMWG) criteria
* Participant must have documented evidence progressive disease as defined by the IMWG criteria either on or after their last regimen
* Other protocol defined inclusion criteria could apply

Exclusion Criteria:

* Any condition, including any uncontrolled disease state that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.
* An active second malignancy or evidence of disease of cancer (other than MM) before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years).
* Cerebrovascular accident/stroke (\< 6 months prior enrollment) or neurologic instability per clinical evaluation due to tumor involvement of the Central Nervous System
* Diagnosis of fever within 1 week prior to study intervention administration
* Part B: Participants planning to undergo a stem cell transplant should not be enrolled to reduce disease burden prior to transplant.
* Other protocol defined exclusion criteria could apply